GlassScriptPhysician profile
Jonathan M Beary
NPI 1134369929
$2,074.99
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,662 · 2020: $115 · 2022: $217 · 2023: $80.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $80.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $80.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,616.17 | 2019 | |
| Zoll Medical Corporation | $119.01 | 2022 | |
| Abbvie INC. | $73.78 | 2022-2023 | Ubrelvy, Qulipta |
| Biogen, INC. | $55.71 | 2019-2023 | Vumerity, Tysabri |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Supernus Pharmaceuticals, INC. | $29.56 | 2019-2020 | |
| Lundbeck LLC | $28.84 | 2020-2022 | |
| Lilly USA, LLC | $26.69 | 2020 | |
| Allergan, INC. | $18.97 | 2020 | |
| Neurocrine Biosciences, INC. | $17.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.22 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.69 | 2022 | |
| Emd Serono, INC. | $15.49 | 2019 | |
| Sk Life Science, INC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Beary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.